AIRO Lung
@AiroLung
Followers
56
Following
30
Media
0
Statuses
25
Thoracic Oncology working group of the Italian Association of Radiotherapy and clinical Oncology (AIRO)
ITALY
Joined June 2019
BREAKING: A new randomized trial demonstrates the benefit of SBRT for patients with EGFR+ stage IV NSCLC. It demonstrates both PFS and OS benefits (n=62). 馃嚚馃嚦 #radonc @EGFRResisters @jillfeldman4
https://t.co/2tYlEtgz4p
9
87
232
Final Results CC001 Addition HA to WBRT+memantine 路 Prevented cognitive failure (HR 0.74,p=0.016) 路 Less symptom burden 6 & 12 mos 路 Less symptom interference 6 & 12 mos 路 Fewer cognitive symptoms overtime 路 NO diff OS, PFS, Toxicity https://t.co/042ZpERT7L
7
42
100
The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments https://t.co/GKILz3sh75
#mdpicancers via @Cancers_MDPI
mdpi.com
Background: About 30% of new non-small cell lung cancer (NSCLC) cases are diagnosed at a locally advanced stage, which includes a highly heterogeneous group of patients with a wide spectrum of...
0
1
6
馃毃@OncoAlert new meta-analysis of SRS vs WBRT in pts with small cell lung cancer in @TheLancetOncol suggesting equitable survival outcomes #radonc #lcsm #btsm
https://t.co/K9KkvPI2A0
2
32
63
Delighted to share our systematic review of heart dose - More stringent IMRT鉂わ笍sparing planning objectives needed - Consensus on contouring and Dose Volume Constraints is lacking - Dose parameters reported for substructures vary substantially https://t.co/P4Nu5fPWVX
pubmed.ncbi.nlm.nih.gov
There is scope to reduce heart radiation dose in lung cancer radiotherapy. Consensus on planning objectives, contouring and DVCs for the heart may lead to reduced heart doses in the future. For IMRT,...
1
18
58
I Venerd矛 di AIRO: webinar su nuove evidenze e temi scottanti in radio-oncologia toracica nel trattamento del NSCLC stadio III 8 aprile 14.30-16.30 https://t.co/AhJaNOdYqe
@AndrearicFili @PaoloBorghetti2 @ALESSIOBRUNI10 @giuliapasello @serenabadellino @stefanovagge @airo_young
ecm.radioterapiaitalia.it
Corso riservati ai Soci AIRO in regola con la quota associativa 2022 Per decenni il trattamento radioterapico adiuvante in pazienti sottoposti a
0
5
6
A very important topic that deserves future strategies to improve this scenario! @JTOonline @IASLC @myESMO @AIOMtweet @AIRO80327989 @finn_corinne @LungCancer_HU @LungCancer_H @ASCO @OncoPolmoneIEO
Despite the advancements in research and treatment for lung cancer, there are still vast disparities across the cancer care continuum, both in the United States and worldwide. Read more in ILCN. #LCSM @jillfeldman4 @ivybelkins @MatthewSchabath
https://t.co/DLUbfomNAV
0
0
1
Very interesting case!
Sato et al. reported the first case of #postoperative #radiotherapy for a #thymic squamous cell carcinoma located on the outflow graft of a left ventricular assist device. https://t.co/HCT6tWx6VF
@OncologyAdvance @IASLC#JTOCRR #openaccess #LCSM
0
0
0
A very important theme!
Continuing with the heart toxicity theme, we are pleased to present a novel Methodology to Investigate the Effect of RT Dose to Heart Substructures on OS. The sensitive structures are the right atrium, right coronary artery, ascending aorta @RT_physics
0
0
0
Longer follow-up shows even greater impact of #radonc SABR for oligometastases in @drdavidpalma's SABR-COMET trial @caro_acro_ca #CARO2020 #CAROVSM2020. Now 22 month increase in overall survival (possibly also driven by post-trial SABR). See @asco_pubs
https://t.co/FwSKQ2l5FJ
1
46
78
Read this study from #JTOCRR Issue 3 and the #COVID19 collection by Fu et al., examining the real-world scenario of patients with lung cancer during the COVID-19 pandemic in China. https://t.co/WjE5WIr7Wo
@IASLC @OncologyAdvance #openaccess #LCSM
0
3
1
LungART: no sign 3yr DFS improvement (43.8 to 47.1%) for adj RT in pN2 IIIa #NSCLC. Importantly no OS benefit, but reduced local relapse (46.1 to 25%), but incrsed death (5.3 to 14.6%); Excess deaths in RT arm mainly from cardio-pulmonary tox, more new cancers @OncoAlert #ESMO20
1
40
76
Pubblicato oggi sul giornale New England Journal of Medicine il lavoro in esteso dello studio clinico ADAURA, una pietra miliare nel trattamento del tumore del polmone. Le nostre congratulazioni al Prof de Marinis, autore di questo importante lavoro @IEOufficiale
0
3
5
Very interesting theory... @JTOonline
According to a study by Shin, Kang and Jeong, combined use of aspirin, statins, and metformin is associated with decreased lung cancer incidence and mortality. #JTO #OncologyResearch
https://t.co/wzNRIj3mhU
0
0
1
AURA3 Fails To Demonstrate OS Benefit For Osimertinib: Osimertinib does not significantly extend overall survival compared with platinum鈥損emetrexed for previously treated advanced non-small-cell lung #cancer pts with an EGFR T790M mutation https://t.co/2VxSf0h27A
#lcsm #nsclc
0
20
34
Moore et al. evaluated survival outcomes of curative and palliative therapies in locally recurrent NSCLC in this real-world analysis published in #JTOCRR. https://t.co/JagCoikHoi
@JTOonline @OncologyAdvance #bccancer #openaccess #LCSM
0
0
0
In an article published in @JTOonline Dr. Myung-Ju Ahn et al. discuss Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status. https://t.co/dAO5zLsbw1
#LCSM #LungCancer #Oncology
0
10
29